NCT02807779View on ClinicalTrials.gov

Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 10, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2022

Conditions
Peripheral Artery DiseaseVascular DiseaseCritical Limb Ischemia
Interventions
DRUG

Dexamethasone infusion

Participants will receive dexamethasone infusion following plain balloon angioplasty

DEVICE

Drug coated balloon

Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty

DEVICE

Plain balloon angioplasty

Participants will receive plain balloon angioplasty only

Trial Locations (2)

94121

San Francisco VA Medical Center, San Francisco

98104

University of Washington, Seattle

All Listed Sponsors
collaborator

University of Washington

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of California, San Francisco

OTHER

NCT02807779 - Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging | Biotech Hunter | Biotech Hunter